Table 4.
Treatment (12 h) | G0/G1 | S | G2/GM | Compound(G0/G1)−CON(G0/G1) |
---|---|---|---|---|
U87-MG | ||||
Control (CON) a | 40.96% | 38.56 | 20.48 | |
DOX (0.8 μM) | 90.65% | 5.52% | 3.83% | 49.69% |
P11A (2, 0.8 μM) | 81.88% | 9.12% | 9.00% | 40.92% |
U251 | ||||
Control (CON) a | 44.48% | 36.81% | 18.71% | |
DOX (0.8 μM) | 71.45% | 15.51% | 13.04% | 26.97% |
P11A (2, 0.8 μM) | 62.39% | 21.92% | 15.69% | 17.91% |
Control (CON): U87-MG and U251 cells were treated without compounds.